BidaskClub Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold

BidaskClub downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research note issued to investors on Wednesday, BidAskClub reports.

Several other research analysts also recently commented on ALNY. Cowen decreased their price objective on Alnylam Pharmaceuticals from $147.00 to $120.00 and set an outperform rating on the stock in a research note on Wednesday, August 7th. UBS Group lifted their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the company a neutral rating in a research note on Wednesday, September 4th. Zacks Investment Research downgraded Alnylam Pharmaceuticals from a buy rating to a hold rating and set a $93.00 target price on the stock. in a research note on Wednesday, September 18th. ValuEngine raised Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. Finally, Stifel Nicolaus set a $116.00 target price on Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 3rd. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of Buy and an average price target of $114.69.

NASDAQ ALNY opened at $77.02 on Wednesday. The stock’s 50-day moving average price is $82.10 and its 200-day moving average price is $78.59. The company has a quick ratio of 6.16, a current ratio of 6.28 and a debt-to-equity ratio of 0.17. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $96.08. The company has a market capitalization of $8.57 billion, a P/E ratio of -10.17 and a beta of 2.40.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.02) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.04. Alnylam Pharmaceuticals had a negative return on equity of 56.42% and a negative net margin of 848.70%. The firm had revenue of $38.20 million for the quarter, compared to the consensus estimate of $42.24 million. During the same quarter last year, the company earned ($1.61) earnings per share. The business’s revenue for the quarter was up 27.8% compared to the same quarter last year. Research analysts anticipate that Alnylam Pharmaceuticals will post -8.21 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Macquarie Group Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 7.3% in the 2nd quarter. Macquarie Group Ltd. now owns 62,288 shares of the biopharmaceutical company’s stock worth $4,520,000 after purchasing an additional 4,215 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 8.0% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 22,369 shares of the biopharmaceutical company’s stock worth $1,623,000 after purchasing an additional 1,653 shares during the period. BlackRock Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the 2nd quarter. BlackRock Inc. now owns 6,537,253 shares of the biopharmaceutical company’s stock worth $474,340,000 after purchasing an additional 109,126 shares during the period. Maverick Capital Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 31.9% in the 2nd quarter. Maverick Capital Ltd. now owns 4,236,016 shares of the biopharmaceutical company’s stock worth $307,365,000 after purchasing an additional 1,025,629 shares during the period. Finally, Platinum Investment Management Ltd. purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $1,644,000. Institutional investors and hedge funds own 94.20% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Featured Article: How is the LIBOR rate calculated?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.